NAION and treatment of erectile dysfunction: Reply from Pfizer [13]

British Journal of Ophthalmology

Volumn 90, Issue 7, 2006, Pages 927-

  Sobel, Rachel E ^a   Cappelleri, J C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL;

DRUG HALF LIFE; DRUG USE; ERECTILE DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERTENSION; INTERVIEW; ISCHEMIC OPTIC NEUROPATHY; LETTER; METHODOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

CARBOLINES; CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; IMPOTENCE; MALE; OPTIC NEUROPATHY, ISCHEMIC; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 33745670619     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.094375     Document Type: Letter

References (4)

1. McGwin G, Vaphiades MS, Hall TA, et al. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006;90:154-7.
2. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
3. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J Sex Med 2005;2:751-8.
4. Assman SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;35:1064-9.